Get the Stockscreener App
100.28
4.19%
-4.39
Palvella Therapeutics Inc stock is traded at $100.28, with a volume of 328.48K.
It is down -4.19% in the last 24 hours and up +9.49% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$104.67
Open:
$103.93
24h Volume:
328.48K
Relative Volume:
1.36
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.99%
1M Performance:
+9.49%
6M Performance:
+320.90%
1Y Performance:
+735.67%
1-Day Range:
$97.19
$105.54
1-Week Range:
$97.19
$105.54
52-Week Range:
$11.89
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
100.28 | 1.24B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Initiated | BTIG Research | Buy |
| Dec-04-25 | Initiated | Craig Hallum | Buy |
| Nov-19-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9%Here's What Happened - MarketBeat
Published on: 2025-12-23 22:49:55 - bollywoodhelpline.com
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path - MyChesCo
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results - MyChesCo
Palvella Therapeutics stock hits 52-week high at 112.4 USD By Investing.com - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighStill a Buy? - MarketBeat
Palvella Therapeutics stock hits 52-week high at 112.4 USD - Investing.com
Palvella Therapeutics, Inc.(NasdaqCM:PVLA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Palvella Therapeutics (PVLA) Price Target Increased by 33.50% to 178.50 - Nasdaq
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Finviz
Will Palvella Therapeutics Inc. stock gain from lower inflation2025 Earnings Impact & Fast Gain Stock Tips - Улправда
Assessing Palvella Therapeutics’ Valuation After Its Rare Disease Momentum-Driven Surge in 2024 - Yahoo Finance
Buy Signal: Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownQuarterly Profit Report & AI Enhanced Execution Alerts - Улправда
Will Palvella Therapeutics Inc. stock attract ESG investorsTrade Signal Summary & Real-Time Market Sentiment Reports - Улправда
How Palvella Therapeutics Inc. stock trades before earningsJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - Улправда
Will Palvella Therapeutics Inc. stock continue upward momentumGlobal Markets & Weekly High Momentum Picks - Улправда
Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells Shares - TradingView — Track All Markets
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
What is the fair value of Palvella Therapeutics Inc. stock nowJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - DonanımHaber
Buy Signal: Is Palvella Therapeutics Inc. stock a buy for dividend growth2025 Price Momentum & AI Powered Trade Plan Recommendations - DonanımHaber
Can Palvella Therapeutics Inc. stock deliver surprise earnings beatMarket Activity Summary & Weekly High Potential Stock Alerts - ulpravda.ru
What is HC Wainwright's Forecast for PVLA FY2027 Earnings? - MarketBeat
FY2026 EPS Estimates for PVLA Decreased by Lifesci Capital - MarketBeat
Palvella Therapeutics announces topline results from Phase 2 TOIVA trial - MSN
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% Following Analyst Upgrade - Defense World
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 6.6% on Analyst Upgrade - MarketBeat
Palvella Therapeutics stock price target raised by Chardan to $174 on cVM trial - Investing.com Canada
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer - Yahoo Finance
Analyst Raises Price Target for PVLA with Maintained Buy Rating - GuruFocus
TD Cowen Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00 - MarketBeat
Adagene, Palvella up after FDA Fast Track tags (ADAG:NASDAQ) - Seeking Alpha
Palvella Therapeutics stock price target raised to $193 at Raymond James - Investing.com Canada
Palvella Therapeutics Says US FDA Grants Potential Lesion Therapy Fast-Track Designation - marketscreener.com
Chardan Boosts Price Target on Palvella Therapeutics to $174 From $110, Keeps Buy Rating - marketscreener.com
Accenture To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
FDA grants fast track designation for Palvella’s skin disease therapy By Investing.com - Investing.com Canada
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas - The Manila Times
Palvella Therapeutics Granted FDA Fast Track Designation - GlobeNewswire
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):